Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $36.6M fell 15.8% year over year, behind the -11.7% change in trailing-twelve-month research & development. Sequentially, it fell 29.9% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.

Context

  • Research & development amounted to 440763.9% of revenue in FY2025, up 159447.5 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -15.8% toward the trailing-twelve-month pace of -11.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$36.6M-29.9% QoQ
Last fiscal yearDec 2025
$158.68M-7.5% YoY
LTMMar 2026
$151.83M-11.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.8%——
1 year-7.5%——
3-year CAGR-0.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
158.68M USD
Year-over-year change
-7.5%
4-year CAGR
+3.4%

Research & Development vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.7% is the 6th highest of 10, against a peer median of -6.9%.
  • Research & development amounts to 489780.6% of revenue for LYEL, versus a peer median of 1409.6%.
LYEL Competitors
Research & Development for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$152.7M USD+75.7%+85.3%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M USD-11.7%-0.1%489780.6%
CABACabaletta Bio, Inc.LTM Mar 2026$151.01M USD+44.8%+53.7%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M USD-32.1%-16.3%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$126.01M USD-0.7%+67.6%—
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M USD-62.3%-19.9%171.1%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$20.65M USD-58.3%-18.4%—
GNLXGenelux CorporationLTM Mar 2026$20.4M USD+3.6%+29.8%254962.5%
AMRNAmarin Corporation plcLTM Mar 2026$18.45M USD-6.9%-13.3%8.6%
Peer median (excluding LYEL) —-6.9%+10.9%1409.6%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.